Related by context. All words. (Click for frequent words.) 89 TAXUS p value 69 TAXUS Express Stent 69 XIENCE V PROMUS Stent 68 PROCTOCORT ® Suppository Hydrocortisone 68 XIENCE V demonstrated 67 ischemia driven 67 #.#/#.# mmHg [001] 66 receiving INTRON 66 mcg kg REBETOL 66 BMS p = 66 Acetate Rectal Suppositories 66 mm Stent 66 mg kg belimumab 66 Cream USP 1 66 binary restenosis 65 TAXUS Liberte Long 65 -#.# mg dL [001] 65 sirolimus stent 65 log# IU mL 65 placebo p = 65 mg kg Hematide 65 events MACE 65 morphometric vertebral fractures 64 myocardial infarction ventricular fibrillation 64 Zometa hazard 64 PROCTOCORT ® Cream Hydrocortisone 64 VANOS TM fluocinonide Cream 64 probable stent thrombosis 64 refractory ischemia 64 Operative mortality 64 atherothrombotic events 64 target lesion revascularization 64 PLX STROKE targeting 63 confidence interval #.#-#.# 63 Taxus Stent 63 IIIa inhibitor 63 mg + GLY 63 plus GP IIb 63 dyslipidemia hypertension diabetes 63 humanized interleukin 6 63 hyperphenylalaninemia HPA due 63 Soriatane R acitretin capsules 63 deep venous thromboses 63 receiving golimumab 63 systemic embolism 63 ARCALYST ® 63 Suppository Hydrocortisone Acetate Rectal 63 patients undergoing percutaneous 63 diameter stenosis 63 stage IIIb IV 63 Adjusted EBITDAR margin 63 arterial thromboembolic events 63 achieved ACR# 63 ACTEMRA TM 62 prednisone prednisolone plus 62 #mg BID [001] 62 workhorse lesions 62 TAXUS 62 Stent thrombosis 62 mcg QD 62 HES CEL 62 reinfarction 62 stent thromboses 62 baseline serum creatinine 62 CI #.#-#.# [002] 62 & s2 = 62 FluCAM arm 62 Meets Primary Endpoint 62 annualized relapse 62 Mg Usa 62 Percutaneous Transluminal Coronary Angioplasty 62 non splenectomized 62 cardiovascular hospitalizations 62 Technical Downtrend Reversal 62 receiving prophylactic anticoagulation 62 Cypher Stent 62 RRa Radical 7 62 EARNINGS IN RETROSPECT 62 repeat revascularization 62 target vessel revascularization 62 placebo dexamethasone 62 plus dexamethasone 62 Events MACE 62 dalteparin 61 nicardipine 61 8mg/kg 61 ARCOXIA 61 severe neutropenia 61 tirofiban 61 definite stent thrombosis 61 intracranial atherosclerosis 61 EGYPTIAN POUND 61 splenectomized 61 Technical Uptrend Continuation 61 MACCE 61 distal embolization thrombus formation 61 Ishak fibrosis score 61 ® fluocinonide Cream 61 approved incretin mimetic 61 ACR# ACR# 61 lispro 61 Mg Uk 61 segment binary restenosis 61 peripheral sensory neuropathy 61 stable angina pectoris 61 cardiovascular hospitalization 61 non valvular atrial 61 lopinavir r arm 61 Erythropoietic therapies may 61 oxycodone CR 61 nonfatal stroke 61 elevated alkaline phosphatase 61 brand ciclesonide HFA 61 ST Segment Elevation 60 FOLFOX4 alone 60 severe renal impairment 60 % Confidence Interval 60 PREZISTA r arm 60 primary hypercholesterolemia 60 BENICAR HCT 60 pyrexia mucositis sepsis febrile 60 #.#mg/dL 60 infliximab monotherapy 60 aplastic anemia AA 60 ZIANA R 60 biochemical relapse 60 plus aztreonam 60 myocardial infarction stroke 60 -#.# mg dL [002] 60 Target Lesion Revascularization TLR 60 TAXUS Stent 60 log# copies mL 60 NYHA Class II 60 death dissection perforation 60 FOLFIRI alone 60 induce orthostatic hypotension 60 primary generalized tonic 60 Technical Downtrend Continuation 60 PROCTOCORT R Suppository Hydrocortisone 60 grams saturated 60 febrile neutropenia 60 metastatic GIST 60 % MID-EAST/AFRICA 60 generalized edema 60 ventricular tachyarrhythmia 60 ATACAND 60 headache nasopharyngitis 60 serum phosphorous 60 VELCADE melphalan 60 mg BID dose 60 sUA 60 linaclotide treated 60 SMARTREND WATCHING FOR 60 overt nephropathy 60 anthracycline taxane 60 revascularizations 60 Oral Fingolimod 60 nonfatal myocardial infarction 59 Folfox 59 Soriatane R 59 ug dose 59 Unstable Angina 59 primary percutaneous coronary 59 plus glycoprotein IIb 59 Myocardial Infarction Study 59 Euro gesteigert und das 59 uncoated stent 59 OPERATING MARGIN 59 nondiabetic patients 59 % ethanol/# 59 neutropenia dehydration dyspnea 59 metastatic malignant 59 Secondary endpoints included 59 metabolic disorders Saizen R 59 oral antidiabetic medication 59 certolizumab 59 angiographic restenosis 59 Soyabean Ext Bulk 59 recurrent VTE 59 ipsilateral stroke 59 NATRECOR R 59 x ULN 59 FOLFOX4 59 plus prednisone 59 CABG p = 59 mequinol 59 adalimumab Humira 59 low dose Iluvien 59 % CI #.#-#.# [001] 59 cyclophosphamide methotrexate 59 hypophosphatemia 59 locoregional recurrence 59 CI #.#-#.# [001] 59 alanine aminotransferase 59 Soybean Meal T 59 Free Survival PFS 59 elevated transaminases 59 mild renal insufficiency 59 mitoxantrone plus 59 -#.# log# copies mL 59 confirmed CCyR 59 sunitinib Sutent 59 mg QD 59 % CI #.#-#.# [005] 59 recurrent ischemia 59 naïve HCV 59 HBeAg negative 59 advanced adenoma 59 TNF Tumor Necrosis Factor 59 severe exacerbations 59 plus COPEGUS 59 besifloxacin ophthalmic suspension 59 tumor lysis syndrome 59 adjunctive placebo 59 g saturated 59 noninferior 59 hemoglobin A1c HbA1c 58 ribavirin therapy 58 4mg/kg 58 HF hospitalization 58 Left Ventricular Ejection Fraction 58 Index AMBGNL closed 58 FROVA 58 quetiapine risperidone 58 LOW PRICE STOCK 58 recurrent glioblastoma multiforme 58 intravesical therapy 58 nonfatal MI 58 bypass graft CABG surgery 58 keloid scarring 58 & co1 = 58 TEAEs 58 candesartan cilexetil 58 placebo p 58 adjunctive ABILIFY 58 duration mediaQueryString 58 CrCl 58 SUBTRACT NET GAIN LOSS 58 ID TLR 58 stented vessel 58 Hazard Ratio = 58 ABG Infralogistics #.# 58 REMICADE monotherapy 58 baseline HbA1c 58 glycated hemoglobin levels 58 nasopharyngitis 58 infarction NSTEMI 58 mU liter 58 Hazard Ratio 58 hemodynamically significant 58 plus methotrexate 58 mg p = 58 plus OBT 58 de novo lesions 58 INEOS ABS India 58 moderate renal impairment 58 undergoing coronary artery 58 reintervention 58 budesonide pMDI 58 peripheral arterial occlusive disease 58 Carotid Revascularization Endarterectomy vs. 58 OS = ISD/#/#/# 58 SpOC SpCO SpMet PVI 58 lumbar spine BMD 58 statistical significance p 58 malignancy HCM 58 grams dietary fiber 58 coronary revascularisation 58 discontinuations due 58 aldosterone antagonist 58 elevated ALT 58 PSADT 58 TAXUS Express 58 draining enterocutaneous 58 Sustained virologic response 58 gout flares 58 Additional Downside 58 titrated glipizide plus 58 cerebrovascular events 58 venous thromboembolic events 58 carotid intima media 58 Fasting blood glucose 58 #,# BID PRICE 58 bronchial hyperresponsiveness 58 Coronary Artery Bypass Graft 58 rosuvastatin #mg 58 angina myocardial infarction 58 resuscitated cardiac arrest 58 coronary revascularization 58 RATIO OF 58 artery reclogging 58 mL/min/#.# m 2 58 microbiologically evaluable 58 Intensive blood glucose 58 MCyR 58 Percutaneous Coronary Intervention 58 myocardial infarction MI 58 valvular disease 58 hip BMD 58 mcg linaclotide 58 FRM averaged #.# 58 maintaining fistula 58 underwent percutaneous coronary 58 ARMS averaged 58 peripheral neuropathy NEC 58 undergo percutaneous coronary 58 ULORIC 58 GP IIb IIIa inhibitors 58 unstable angina UA 57 PEGylated Fab fragment 57 HBeAg negative patients 57 Global Nonlife Insurance 57 cytogenetic response 57 PEGylated anti 57 Pulse CO Oximetry Pulse 57 colorectal adenoma 57 Montgomery Asberg Depression 57 undergoing percutaneous coronary 57 hypercholesterolemia 57 Index CDAI score 57 EFFECTIVE TAX RATE 57 ZIANA ® 57 Secondary endpoints include 57 VANOS R fluocinonide 57 severe hypoglycemic 57 Castration Resistant Prostate Cancer 57 Lactic acidosis 57 WITH HIGHER GUSTS 57 R# #mg BID 57 achieved PASI 57 p = NS 57 everolimus eluting stents 57 zolmitriptan 57 microbiological eradication 57 CCyR 57 Non GAAP Gross Margin 57 thromboembolic events 57 Ranolazine 57 WINNING BID PRICE 57 POST PAID NET ADDS 57 paclitaxel eluting stents 57 pentadentate logo R 57 thromboembolic complications 57 #mg BID [003] 57 cisplatin vinorelbine 57 thromboembolic 57 BSE SMALLCAP index 57 bone marrow reticulin 57 herpetic keratitis 57 -yil 57 mL/min/#.# m2 57 aspirin clopidogrel 57 Evoclin R 57 angioplasties stents 57 stent binary restenosis 57 LVEF 57 nonfatal myocardial infarction MI 57 g trans fats 57 3hours #mins #.#secs M 57 Median progression 57 binary restenosis rate 57 calculated creatinine clearance 57 CYPHER ® Stent 57 leukopenia 57 repeat paracentesis 57 Nephrol Dial Transplant 57 aminotransferase elevations greater 57 DJI #.# 57 PREPAID WHOLESALE 57 thrombotic events 57 confidence interval CI 57 highly emetogenic 57 unstable angina pectoris 57 Median PFS 57 unfractionated heparin UFH 57 Asian-American/Pacific Islanders 57 R rilonacept Injection 57 comparator arm 57 #mg/dL [001] 57 chronic thromboembolic pulmonary 57 STRIDE PD 57 Back Guar 57 plus gemcitabine 57 IIIa inhibitors 57 Drug eluting stent 57 specific alkaline phosphatase 57 glycoprotein IIb IIIa inhibitor 57 Zevalin R Ibritumomab 57 invasive aspergillosis 57 Severity MSCS score 57 Target Vessel Revascularization 57 complete cytogenetic response 57 cell lymphoma CTCL 57 Primary endpoints 57 P = .# 57 Nasdaq CPTS developer 57 reblockage 57 endarterectomy 57 HBeAg seroconversion 57 reduce serum phosphate 57 paroxysmal AF 57 Solid Tumors criteria 57 -#.# log# 57 ARB telmisartan 57 PRADAXA #mg 57 PSA nadir 57 #mg/day [002] 57 COPD exacerbation 56 hypertension congestive heart 56 mmHg p = 56 plus MTX 56 Major Adverse Cardiac 56 postoperative AF 56 Response Evaluation Criteria 56 advanced adenomas 56 HBeAg positive patients 56 VT VF 56 prolonged QT interval 56 posaconazole 56 vertebral fracture 56 transplantation HCT 56 ribavirin RBV 56 icatibant 56 mso footer margin 56 - FUTURES CASH YIELD [001] 56 By Sylvie Belmond 56 Evoclin TM clindamycin Foam 56 active ankylosing spondylitis 56 Median survival 56 CIMZIA TM certolizumab pegol 56 % CI #.#-#.# [007] 56 achieved statistical significance 56 pCR 56 placebo Hazard Ratio 56 LAST QUARTER ANNUALIZED SALES 56 Restenosis 56 hypokalemia 56 nonvertebral fractures 56 failure TVF 56 intravascular hemolysis 56 transurethral resection 56 SGPT 56 baseline A1C 56 NNT = 56 EXCEPT FOR SHARE 56 lumbar spine bone 56 hydroxymethyl coenzyme 56 mainline passenger RASM 56 myocardial infarction 56 prostate TURP 56 Acute Coronary Syndromes 56 urinary N telopeptide 56 angiotensin converting enzyme inhibitor 56 Lupuzor ™ 56 -#.# USD JPY [003] 56 ST elevation myocardial 56 mcg BID 56 MONTHLY DATA ARPU 56 hypercalcemia 56 symptomatic VTE 56 evaluating picoplatin 56 Acute Myocardial Infarction 56 nonsignificant difference 56 intravenous RSD# 56 AUD NZD gaining 56 RGT arm 56 ZOLINZA 56 pooled comparator 56 chlorambucil 56 silent ischemia 56 tolterodine ER 56 sirolimus eluting 56 MADRS score 56 urate lowering therapy 56 CAPEX SERVICE REVENUE 56 INCB# [003] 56 CIMZIA TM 56 stent thrombosis 56 vessel renarrowing 56 β blocker 56 TAXUS Express Atom Stent 56 #.#mmol L [001] 56 dapagliflozin plus 56 Nesiritide 56 #mg QD [002] 56 complete cytogenetic 56 CYPHER Stent 56 hypercholesterolaemia 56 Rating Scale MADRS 56 oral antidiabetes 56 Inc. Alcortin TM 56 % CI #.#-#.# [003] 56 heparin induced thrombocytopenia 56 CI -#.# 56 rebleeding 56 FOLFOX6 56 Hypotension 56 mg TID 56 ruboxistaurin 56 rizatriptan 56 Severe hypoglycemia 56 systemic corticosteroid 56 ARMs averaged #.# 56 DAS# CRP 56 weekly CSBMs 56 -#.# ± [001] 56 graft occlusion 56 TAXUS Element Stent 56 xanthine oxidase inhibitor 56 BY RON DZWONKOWSKI 56 salmeterol HFA MDI 56 underwent surgical resection 56 fatigue asthenia 56 recurrent DVT 56 percutaneous intervention 56 endophthalmitis 56 WEST NORTHWEST NEAR 56 activated partial thromboplastin 56 biphasic insulin aspart 56 abacavir lamivudine 56 OF NET CAPITALIZATION 56 hematuria abrupt 56 REYATAZ r arm 56 corticosteroid dose 56 Injecte . 56 intima media thickness 56 UNCERTAINTY OF FUTURE FINANCIAL 56 clodronate 56 Cimzia TM 56 neurologic progression 56 perioperative complications 56 doxazosin 56 leukemia AML 56 underwent resection 56 mean baseline A1C 56 cerebrovascular accident 56 Scale cognitive subscale 56 MAGE A3 ASCI 56 Hb A1C 56 Luvox fluvoxamine 56 AA Amyloidosis 56 PASI scores 56 primidone 56 MULTAQ 56 eplerenone 56 invasive candidiasis 56 EXJADE 56 Contract Compliance Ariba 56 Hazard Ratio HR 56 cytopenias 56 onset atrial fibrillation 56 NMIBC 56 luminal diameter 56 benazepril 56 metoprolol tartrate 56 5-FU/LV 55 microalbuminuria 55 placebo PBO 55 oxycodone IR 55 ARIXTRA 55 carotid artery blockage 55 rimonabant #mg/day 55 至 55 hemoglobin A1c levels 55 infusional 5-FU/LV 55 nadolol 55 antiarrhythmic drug 55 Annualized Distribution 55 BENICAR 55 relapsed MM 55 â ‰ ¥ 55 irbesartan 55 MISSOURI TOTAL 55 Scale EDSS 55 mg Lucentis 55 INDIVIDUALS WHO 55 oral allopurinol 55 Acute Coronary Syndrome 55 mg q#h 55 ketoconazole USP Gel 55 stenoses 55 progression TTP 55 LymphoStat B belimumab 55 sotalol 55 glycoprotein IIb IIIa inhibitors 55 sustained virological response 55 Postoperative complications 55 LOVENOX 55 tapentadol ER 55 acarbose 55 RLAI 55 Aflibercept 55 saline placebo 55 infusional 55 Non inferiority 55 coronary stenosis 55 TAXUS Liberté stent 55 relapsed refractory multiple myeloma 55 minimally symptomatic 55 Hereafter Inception Iron Man 55 beta blockers ACE inhibitors 55 elevated LDL cholesterol 55 #-#-# drlg [002] 55 KRAS mutations occur 55 ALVESCO 55 achieved sustained virological 55 % mlink 55 Abciximab 55 white petrolatum Ointment 55 revascularisation 55 lowest tertile 55 hepatorenal syndrome 55 Angiographic 55 QTcF 55 Flu Cy 55 TNF antagonist 55 RECIST Response Evaluation Criteria 55 NET EARNINGS 55 atrioventricular block 55 renal artery stenosis 55 undergoing coronary angiography 55 glulisine 55 NSTEMI 55 REYATAZ r 55 mild renal impairment 55 Network Uptime Money 55 achieved sustained virologic 55 thromboembolic disorders 55 stable angina 55 postoperative complication 55 CR CRu 55 sirolimus eluting stents 55 aspartate aminotransferase 55 leucopenia 55 Score TOS 55 adenomatous polyps 55 composite endpoint 55 sirolimus eluting stent 55 mCi kg 55 primary patency 55 HbA1c levels 55 atypical ductal hyperplasia 55 spinal cord compression 55 depth FFLI #.# 55 angioplasty stenting 55 sustained virologic response 55 Engerix B 55 arterial thrombosis 55 periprocedural 55 secondary efficacy endpoint 55 Val HeFT 55 response CCyR 55 salmeterol fluticasone 55 BY CAROL CAIN 55 FDA Approves Novel 55 recurrent atrial fibrillation 55 mg qd 55 asymptomatic carotid stenosis 55 nonvertebral 55 6R BH4 55 6 sulfatase 55 -#.# USD JPY [001] 55 creatinine clearance 55 liver histology 55 thickness IMT 55 abciximab 55 CI = 55 Alzheimer Disease Assessment 55 ExTRACT TIMI 55 median PFS 55 Pharmacokinetics PK 55 acute myocardial infarction AMI 55 nadroparin 55 glycated hemoglobin HbA1c 55 upper gastrointestinal bleeding 55 nilotinib Tasigna ® 55 SEACOR HOLDINGS 55 splenectomized patients 55 cerebral vasospasm 55 GOUT 55 statin monotherapy 55 pT3 55 FluCAM 55 sustained ventricular tachycardia 55 corrected QT interval 55 Shemiran N. 55 abdominal pain abdominal discomfort 55 Homes Sold tbr 55 Nasdaq# futures 55 defibrillator CRT D 55 infarction STEMI 55 carotid stenosis 55 triglyceride concentrations 55 patients undergoing CABG 55 PREZISTA r 55 creatinine ratio 55 ALT elevation 55 venous thromboembolic disease 55 Ltd. Eurodollars 55 elevated uric acid 55 Repliform R revenues 55 bivalirudin monotherapy 55 ADCS CGIC 55 SORT OUT III 55 proximal DVT 55 CIMZIA ™ 55 IM progesterone 55 serum phosphate 55 oral FTY# 55 achieved CCyR 55 hypomagnesemia 55 eptifibatide 55 serum triglycerides 55 lopinavir r 55 fasting plasma glucose FPG 55 coronary intervention 55 lymphocytosis 55 NATRECOR ® 55 Teriflunomide 55 del 5q MDS 55 CR nPR 55 TLUS 54 Crohn Disease Activity 54 #-#-# drlg [001] 54 evaluable 54 oral rivaroxaban 54 BARACLUDE ® 54 severe aortic stenosis 54 apnea hypopnea index 54 serum transaminases 54 tumor progression TTP 54 receiving ISENTRESS 54 refractory NSCLC 54 coronary revascularization procedures 54 elevated triglyceride levels 54 retinal vein occlusion 54 desvenlafaxine succinate 54 CTEPH 54 pancreatic resection 54 REVIVE Diabetes 54 ATV RTV 54 vasculopathy 54 CorVue ™ 54 prespecified secondary 54 chemoradiation therapy 54 alanine transaminase ALT 54 CK MB 54 BY OPERATOR YoY 54 Infarction 54 postoperative pulmonary 54 lymphoma CTCL 54 nmol liter 54 - NET INCOME [015] 54 recurrent myocardial infarction 54 fraction LVEF 54 seropositive patients 54 fibrinolysis 54 thromboembolism 54 left ventricular dysfunction 54 atopic asthma 54 pmol liter 54 EURIDIS 54 flutamide 54 noncardiac 54 elevated serum creatinine 54 ischemic complications 54 serum aminotransferase levels 54 Unstable angina 54 glycosylated hemoglobin HbA1c 54 endometrial thickness 54 Dow Jones DJc1 54 neoplasia PIN 54 death reinfarction 54 neointimal 54 inadequate glycemic 54 INVEGA ® 54 Green Party Grune 54 onset diabetes mellitus 54 thrombocytopenic 54 somatostatin analog 54 perioperatively 54 azilsartan medoxomil 54 superficial femoral 54 PAOD 54 Apolipoprotein E4 54 stent thrombosis blood clots 54 unfractionated heparin 54 adenoma recurrence 54 serum triglyceride levels 54 ejection fractions 54 pain palliation 54 recurrent coronary 54 NOLVADEX 54 noninferiority 54 esophageal erosions 54 diabetic gastroparesis 54 specific antigen PSA 54 Illusionist Toy Story 54 Kaplan Meier analysis 54 mIU ml 54 DDR2 PC# 1GB Kit 54 neointimal hyperplasia 54 LHON 54 NOTE YOU WILL 54 COUNTIES IN EAST CENTRAL 54 left ventricular systolic 54 artery stenosis 54 lipid lowering agents 54 acute coronary syndrome 54 DAS# [002] 54 beta 1a 54 ximelagatran 54 Knutmania led 54 CRESTOR #mg 54 urge urinary incontinence 54 Doxil ® 54 % 3C/script 54 nonobstructive CAD 54 % CI #.#-#.# [006] 54 carotid endarterectomy 54 torsade de pointes 54 ertapenem 54 Stainless Bar 54 EGFR TKI 54 -BODEN 54 occlusive disease 54 Vaccine Recombinant 54 metformin hydrochloride 54 hypertriglyceridemia 54 g saturated fat 54 HMG CoA reductase inhibitors 54 atheroma volume 54 hepatic metastases 54 Thal Dex 54 ACR# responses 54 FCEc1 54 mg ustekinumab 54 FFR guided 54 interferon alfa 2a 54 cervical intraepithelial neoplasia 54 EARLY DEBT REPAYMENT NET 54 highest tertile 54 oral vancomycin 54 macrovascular events 54 g carbo 54 endometrial hyperplasia 54 receiving VICTRELIS 54 mmol l 54 Virologic 54 progressive dyspnea 54 -#.# mm Hg 54 colesevelam HCl 54 aspartate aminotransferase AST 54 LV dysfunction 54 baminercept 54 HbA1C levels 54 SELENA SLEDAI score 54 myocardial infarctions 54 albumin excretion rate 54 cholesterol LDL C 54 OF SERVICE REVENUES 54 Mean Symptom Complex 54 DRY WEATHER 54 trivial Klatsky 54 IXIC gained 54 octreotide LAR 54 index # rose 54 unresectable 54 #.#g/day 54 concomitant antibiotics 54 TOPX gained 54 biochemical recurrence 54 acutely decompensated congestive heart 54 ug kg 54 DES implantation 54 SOXX gained 54 HeFH 54 thrombotic complications 54 Partial Response 54 CMV disease 54 Stainless Rod 54 postprocedure 54 serum prostate 54 bifurcated lesions 54 Aegon NV +#.# 54 rimonabant #mg 54 #R #R #R [002] 54 pegylated interferon alpha 54 CommVault QiNetix DataMigrator QNet 54 OGTT 54 colorectal carcinoma 54 ACEI ARB 54 bortezomib refractory 54 unproven detoxification 54 folic acid takers 54 bleeding pallor 54 pT2 54 beclomethasone dipropionate 54 #mg QD [001] 54 Index CDAI 54 hyperlipidaemia 54 decompensated heart failure 54 basal cell carcinoma squamous 54 antiplatelet medications 54 Thrombolysis 54 stage IIIB 54 ADD BACK CHARGE ON 54 LANTUS R 54 ACR# response 54 renarrowing 54 mcg kg 54 four FREE Quotes 54 serum urate 54 glimepiride 54 clopidogrel Plavix 54 intracranial hemorrhage ICH 54 alanine aminotransferase ALT 54 symptomatic intracranial hemorrhage 54 CHD CVD 54 PNH patients 54 contrast induced nephropathy 54 undergone radical prostatectomy 54 IXIC climbed 54 necrotizing pancreatitis 54 diarrhea CDAD 54 Peg IFN 54 underwent CABG 54 p = #.# [004] 54 pericardial effusion 54 XELOX 54 p = 53 HBeAg 53 μg dose 53 rFVIIa 53 CRp 53 ischemic cardiomyopathy 53 urgent coronary revascularization 53 bi ventricular pacing 53 periprocedural MI 53 receiving SIMPONI 53 multivessel disease 53 symptomatic atrial fibrillation 53 statistically significant p = 53 detectable HCV RNA 53 opioid induced bowel dysfunction 53 renal insufficiency 53 q#h 53 BRIM2 53 Secondary endpoints 53 TOTAL FG 53 Nonoperating expenses 53 venlafaxine XR 53 GOVERNMENT MEETINGS 53 elevated hsCRP 53 endoscopic remission 53 NSTE ACS 53 pravastatin therapy 53 evaluable subjects 53 ON ANY LOT 53 MOUNT HOLLY HAS ISSUED 53 Q2W 53 imipenem 53 carboplatin paclitaxel 53 Psoriasis Area 53 aspirin beta blockers 53 μmol l 53 HAM D# scores 53 diabetes mellitus DM 53 cilostazol 53 THIS SITE AT 53 recurrent GBM 53 tumor recurrence 53 Guinness NF H 53 commercializing dermatological products 53 OADs 53 mmHg diastolic 53 echocardiographic parameters 53 angiographic outcomes 53 SOMERSET BUREAU 53 impaired glucose metabolism 53 recurrent venous thromboembolism 53 #.#ng/ml 53 bridging fibrosis 53 nasopharyngitis headache 53 HOMA IR 53 recurrent genital herpes 53 FTSE/ASE-# small cap 53 - GROSSDebit Programs 53 renal dysfunction 53 enoxaparin 53 vertebral fractures 53 partial remissions 53 dizziness nausea diarrhea 53 Ophena TM 53 CVD mortality 53 Penguin NF P 53 Quirky chanteuses Florence 53 lumen diameter 53 ACTOplus met